Figure 6.

Reported RRs (95% CI) for cardiovascular outcomes in individuals in the top compared with those in the bottom third of SDMA concentration. I² (95% CI) was 69% (36%, 85%) for CVD, 77% (37%, 92%) for CHD and 27% (0%, 92%) for stroke. BRUNECK indicates Bruneck Study; CHD, coronary heart disease; CVD, cardiovascular disease; DHS, Dallas Heart Study; GetABI, German Epidemiological Trial on Ankle Brachial Index; KAROLA, Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung; PAD, peripheral arterial disease; RRs, risk ratios; SDMA, symmetric dimethylarginine.